Home / Transcripts / American Vanguard Corporation (AVD) · November 9, 2026

American Vanguard Corporation (AVD) Earnings Call Transcript

November 9, 2026

New York Stock Exchange US Materials Chemicals earnings 35 min

Earnings Call Speaker Segments

Robert Winters executive
#1

Thanks, operator. Good afternoon, everyone, and welcome to the third quarter 2026 earnings review conference call for American Vanguard. Dak Kaye, our Chief Executive Officer, and Matt Horwath, our Chief Financial Officer, will lead the prepared remarks. Once they finish, we'll open the line for questions. You can find a copy of today's press release and the supplemental slides on our website. Shortly after this call, a webcast replay and a transcript of the event will be posted to our website as well. Before we get into the presentation, we want to remind everyone that the press release issued today and some of the comments made on this call include non-GAAP figures and forward-looking statements. Those forecasts could differ materially from actual results. Please see the cautionary language in our press release and slides, along with the risk factors described in our SEC filings, all of which are available on our website. At this point, it's my pleasure to hand the call over to CEO Dak Kaye.

Dak Kaye executive
#2

Thanks, Bobby, and hello everyone — glad to have you on American Vanguard's third quarter 2026 earnings conference call. During our previous call, I noted that a successful 2026 would hinge heavily on how the second half of the year played out. I also talked about the tough and fast-moving crosscurrents bearing on worldwide ag markets and on our customers. I indicated we were achieving solid headway in reducing our cost base and in generating commercial gains no matter what the environment throws at us. It's a pleasure to report that these efforts are gaining traction, and that the improvement underway at American Vanguard keeps expanding and speeding up. The 44% rise in prepayments versus the same quarter a year earlier demonstrates both the strength of our portfolio and our customers' dedication. Sadly, today's market conditions aren't helping us at all, particularly beyond the US, where El Niño is hitting our business hard. Set against broadly tough macroeconomic circumstances for agricultural markets worldwide, distributors and retailers keep purchasing only as needed and holding inventories tight. That holds true in every geography where we operate. I'd like to restate the three points from my remarks last quarter, since they remain the correct yardstick for our progress. First, our commercial execution in the US keeps outperforming. Second, the cost measures we implemented in the first half are paying off in absolute terms. Third, we're constructing a new product engine that will fuel growth across the coming several years. Before I walk through the quarter's results at a high level, let me touch briefly on market conditions. On the whole, business conditions across global agriculture have largely deteriorated, driven by the fallout from the Middle East conflict, elevated interest rates and — especially for our international markets — severe weather tied to the Super El Niño, which has brought drought-like conditions to some regions and flooding to others. We continue to concentrate on strengthening customer relationships by delivering excellent service and paying close attention to what customers need, while at the same time accelerating the creation and introduction of new products, with the goal of always serving as a solutions provider wherever we meet our customers. Looking at our home market, the US crop protection sector remained difficult during the third quarter, as the agricultural economy kept facing pressure from multiple directions simultaneously, including the ongoing elevated cost of capital as well as higher fuel and fertilizer costs resulting from the ongoing Middle East conflict. To be more specific, in the US, bigger transportation costs in the shape of soaring diesel prices — climbing more than 40% during the third quarter by itself and over 80% year-to-date in 2026 — are hurting not just customer behavior but our gross margins too, as the industry fights to catch up and lift our pricing to capture this steeply and swiftly climbing cost. The savings we expected from shutting down our LA manufacturing operation and moving production to our Alabama facility have been delivered on the operational side; however, those savings have been more than canceled out by the big jump in transportation costs. Looking further out, we continue to expect those savings to show up once diesel prices settle back to a more typical level. Until then, we are implementing price rises wherever we can in order to offset the increased fuel expenses; in this environment of climbing input and transportation costs, farmers are additionally dealing with commodity prices that stay at fairly low historical levels when adjusted for inflation; it is also worth noting that US government aid is projected this year to account for more than 40% of total net farm income, compared with 25% a year earlier. For some longer-term context, over the past 30 years, US government aid to farmers averaged nearer to 18% to 19% of total net farm income. All of that combined has created a lot of uncertainty, and growers in the distribution channel are still being cautious in how they buy. Now for the quarter's results: net sales were $108 million, a 9% decline from the same period a year ago, and adjusted EBITDA was basically breakeven, which is $8.3 million lower than the prior year period. US crop sales were down 2% in the quarter. As we mentioned in August, some of our cotton portfolio sales shifted out of the second quarter and into the third because customers purchased closer to when they needed the product. That shift showed up, with Folex sales coming in at double what they were in the prior year quarter. We saw a decline in herbicide and granular soil insecticide sales, and the main reason was timing compared with last year. Our specialty business—covering turf, ornamental, home, lawn and garden, and public health—also posted a 2% decrease for the quarter, driven largely by weaker sales at OHP, our ornamental and greenhouse operation; that looks like another timing matter, since orders so far in Q4 have been strong. As I noted near the start of my remarks, conditions in our international markets have stayed tough, and the environment got worse as the third quarter went on. El Niño is still hurting our Central America operations — drought on the Pacific side, too much rain on the Atlantic side. On top of that, Mexico took a hit from low crop prices and fierce competition from generics, which squeezed sales and margins considerably. Brazil also struggled: political uncertainty, high copper prices that drove up the cost of our fungicide, and growers postponing purchases all led to sales coming in below expectations. Australia looks different — Flute, our fungicide there, now carries a cereals label and is doing really well. Across every market our approach doesn't change: stay close to customers, deliver service and solutions, and control what we can control. Now, on the topic of managing the things that are within our control, we've finished the two footprint moves that we told you about back in March. To start, the consolidation of our Los Angeles plant is done, and synthesis production is now up and running at our Axis, Alabama location. That shift should deliver savings of at least $4 million per year, and Q3 marked our first full quarter realizing those savings. Manufacturing performance during the third quarter was excellent. Next, our move of headquarters to Irvine is finished, which saves roughly half a million dollars annually. As the third quarter wrapped up, we picked up four US brands and registrations from Syngenta. In addition, we signed a distribution agreement with Sipcam Agro. Together, these portfolio additions are expected to contribute $15 million to $20 million in annualized revenue across the coming 12 months, and they'll support future top-line growth together with our organic new product introductions. On the topic of new products, I'm happy to share that we've brought 10 new products to market year-to-date, largely smaller third-party distribution items in our international markets. Even more significant, we'll be introducing Duro LQ, a liquid-based corn insecticide, in the US during Q4; our expectations for this product are high. As a reminder, our target is still 15 new product launches generating $100 million in annualized revenue by 2030. New products fuel revenue growth, which is why putting resources here ranks among the most important things we can do; during the quarter, we made several new additions to management. Herman Castro, whom we mentioned on last quarter's call, has come aboard to drive new product development; in addition, Markelt has joined as our new US crop president. Mark is a veteran of the industry whom I've worked with before. Most recently, Matt Horwath has come on board, stepping into the CFO role. Before handing the call to Matt, I'd like to take a brief moment to welcome him to American Vanguard. He's been in the role for 4 months already, and he's clearly come in at full speed, which is just what I anticipated. His background, drive, new viewpoint, and leadership will be important for pushing forward the execution of the numerous initiatives we have, and also for concentrating on simplifying, prioritizing, and delivering throughout the organization. There's a great deal of work ahead of us, and I'm glad Matt is here with us. So with that, I'll hand things over to Matt so he can take everyone through the financials in greater detail. After he finishes his review, I'll come back with our 2026 full-year outlook and where we stand on our progress toward our 2028 targets. Matt?

Matt Horwath executive
#3

Thanks, Dak, and good afternoon, everyone. Before I walk through the quarter's financial results, I want to share a few thoughts on my joining American Vanguard. It's a significant moment for this company, and I'm thrilled to be aboard and thankful for the warm reception from Dak, the board, and the leadership team. Over the course of my career, I've served as a strategic finance partner to the businesses I've backed, with a focus on operational excellence, financial discipline, and producing free cash flow that creates long-term value for shareholders. What attracted me to American Vanguard is a clear route to sustainable financial growth, resting on a foundation that correlates strongly with opportunities I've been involved with during my career. American Vanguard operates in attractive, resilient markets, and we have a focused, differentiated product lineup. That lineup is shielded by significant entry hurdles — including strong customer access channels, entrenched positions in the geographies we serve, and a skilled sales force with both broad commercial reach and technical know-how. It stays fresh thanks to distinctive R&D capabilities that let us create and introduce products competitors find hard to replicate. On top of that base, I see meaningful opportunities spanning multiple years to grow margins and boost productivity. Over the longer term, gross margin gains will come from better manufacturing efficiency and utilization, from launching new products and scaling them, and from disciplined pricing management. Underneath gross margin, there's a real chance for us to update how the back office works and get more out of our fixed costs. Doing that doesn't require us to stretch past what we're good at; it means running the business we've already got well, improving operational efficiency, bringing financial discipline throughout the company, and boosting how much free cash flow we generate. The plan is right in front of us, and the leadership team is eager to carry it out. Execution is what matters, and I'm confident that over time it will produce notably stronger operating performance, which in turn will give us room to establish a repeatable, disciplined framework for allocating capital. While things are tough in the industry at the moment, I have confidence in what we can do over time: increase revenue more quickly than the markets we serve, expand EBITDA more quickly than revenue, and grow unlevered free cash flow more quickly than earnings. That's the way we plan to build lasting value for shareholders, and I'm eager to update you on how we're doing. Now to our results for the third quarter of 2026: sales came to $108 million, versus $119 million during the same quarter of 2025 — a 9% decline. Across the first nine months, sales reached $349 million, a 4% drop from $364 million the year before. For the quarter, U.S. crop sales were down 2%, because higher sales of our growth regulators Folex and Citrus Fix, Thimet, a granular soil insecticide, and our fungicide portfolios were more than offset by lower sales of soil fumigants and herbicides. U.S. crop sales rose 3% on a nine-month basis. U.S. specialty sales declined 2% in the quarter, as gains in our turf fungicide and in Naled, our mosquito adulticide, were outweighed by softer sales of our ornamental portfolio and insect growth regulators, largely reflecting inventory stocking patterns. Across nine months, U.S. specialty sales were up 6%. International sales fell 17% in the quarter and 14% over the first nine months. The quarterly and year-to-date declines stemmed mainly from unfavorable weather in Latin America tied to El Niño. Partly offsetting those decreases were stronger soil fumigant sales and ongoing growth in Ecuador, where our commercial operations are expanding. Gross margin for the quarter came in at 24.2%, versus 28.7% in the third quarter of 2025. Manufacturing performance improved compared with the prior year, yet that improvement was more than offset by higher freight costs, which cut gross margin by roughly 250 basis points, along with increased raw material costs and reduced fixed cost leverage in Q3. The price increases we put in place over the course of the year merely canceled out the inflationary pressure we saw in the first half—they did not address the inflation that persisted into the third quarter. When you look at the first nine months as a whole, gross margin came in at the same level as last year. On a GAAP basis, operating expenses were $34.2 million, and that figure includes $3 million tied to amortization of intangibles from acquisitions, $3 million for transformation and executive transition costs, and $300,000 in stock-based compensation. Non-GAAP operating expense was $27.8 million, which is $800,000 below what we reported in Q3 of last year. That reflects our continued capture of productivity gains from transformation work and targeted investments aimed at executing our new product introduction roadmap, all while countering ongoing inflationary pressure. In the quarter, transformation costs totaled $1.7 million, which is $300,000 less than in Q3 of the prior year. For the quarter, adjusted EBITDA came in at roughly break-even. That's down $8.3 million versus the third quarter of 2025. The decrease came from lower gross profit—especially on international sales, where El Niño weather conditions put heavy pressure on demand—along with significantly higher freight costs. Those factors outweighed the benefit we got from lower operating expenses. We ended the quarter with $84 million in cash, which is $40 million higher on a sequential basis, thanks to strong customer prepayments during the quarter. On top of that, we're continuing to carry out our working capital initiatives, including a $4.9 million year-over-year cut in inventory, which reflects tighter production planning by the team and our improved sales, inventory, and operating planning process. Our longer-term target of two inventory turns remains our focus. At the close of the quarter, total debt stood at $267.7 million, while net debt came in at roughly $183.8 million — a sequential reduction of $40 million, which reflects the cash performance we discussed earlier in the quarter. When measured for debt covenant purposes under our first lien term loan, gross leverage ratio ended the quarter at 6.5 times, compared with a covenant ceiling of 6.7 times. Given the fourth-quarter guidance we've provided and the cash generation that accompanies it, we anticipate leverage will decline from this level as we close out the year. Looking ahead, the fourth quarter typically is a time when we collect a meaningful portion of customer prepayments. In Q4 2025, we collected about $55 million from prepayments and early pay. As Dak pointed out, prepayments came in faster during Q3 2026, and right now we expect prepayment and early pay collections to reach $45 million in Q4. We anticipate that net working capital will contribute positively to liquidity in the fourth quarter. With that, I'd like to return the call to Dak for a few more comments before we open up for Q&A. Dak?

Dak Kaye executive
#4

Thank you, Matt. Before we begin taking questions on the call, I'd like to walk through what we see ahead for the balance of 2026 and what that means for 2027 based on where things stand today. I'd also like to discuss the longer term and restate the targets we've set for ourselves. Let's move now to our view of the rest of 2026. Given the tougher conditions in the US and international markets, along with third-quarter results that came in below what we expected, we're reducing our full-year guidance for revenue and adjusted EBITDA. Full-year revenue is now projected at $500 million to $530 million, compared with the $530 million to $550 million range we gave previously. On adjusted EBITDA, our expectation is now $36 million to $40 million, versus the earlier forecast of $44 million to $48 million. As I mentioned earlier in my remarks, the main reasons for this revision are softer results in our international business than we had anticipated and our inability to raise prices quickly enough to offset higher fuel costs and increases in underlying raw materials. I'd also like to spend a moment briefly reviewing our fourth-quarter 2026 outlook against how we performed in the fourth quarter of 2025 on both the top line and adjusted EBITDA. A number of unique internal and external factors weighed on last year's fourth quarter, and those will not recur this year. Those factors were reflected in the weak results from last year's fourth quarter, though the impact was partly offset by upfront royalty income, which lifted sales and adjusted EBITDA by more than $11 million. Even so, we expect to surpass last year's fourth-quarter adjusted EBITDA and top-line results, with projected net sales of approximately $166 million, a 10% increase over the year-ago period, and projected adjusted EBITDA of $21 million, roughly 25% higher than last year's fourth quarter. As a reminder, the fourth quarter has historically been our strongest quarter for both sales and EBITDA. Three factors underpin our expectation of better performance in this year's fourth quarter. Here, I'll concentrate on the items presented in the adjusted EBITDA bridge slide, which is slide 8 in the Quarter 3 presentation. First and most significant, we anticipate gains from higher volumes and an improved mix, fueled by stronger US crop and specialty sales and comparatively better international performance; this stems mainly from new energized and focused commercial teams operating under a defined plan to grow sales, particularly US crop herbicide volumes, granular soil insecticides, and specialty sales in the ornamental market. Contracted annual volume increases with customers will fuel the year-over-year sales growth in LatAm, along with the Flute label extension in Australia. Sales from the newly added products and Duro LQ should be incremental relative to last year's fourth quarter. Let me be clear: this isn't because we're seeing a meaningfully better environment year-over-year in these markets. What we're forecasting as improvement has more to do with controlling the things we can control and executing at a higher level no matter what the environment does. On top of that, the year-ago fourth quarter contained specific mix and timing issues — in both the US and international markets — that hurt results and that we don't anticipate recurring this year. Second, those better sales should drive better absorption of fixed manufacturing costs year-over-year. Third, we anticipate cost savings from shutting down our LA plant, plus additional gains from ongoing efforts to keep lowering operating expenses. Partly offsetting all of this, we expect transportation costs to run higher — driven mainly by elevated diesel prices — and to keep weighing on performance year-over-year. Let me wrap up by reminding everyone where we're headed. I've said it often: accountability means results, and for a public company those results show up in the numbers; we're focused on driving revenue growth, higher manufacturing utilization, greater operating cost efficiency, and lower overhead costs. Together, those lead to higher gross margins, higher operating margins, and sustainably higher EBITDA. Near term, our top priority is still getting our EBITDA margin into double digits as soon as possible. On the top line, we expect to hit an annualized run rate exceeding $600 million in sales by the back half of 2028, roughly 20% above our 2025 goal. Beating that timeline will depend largely on how US and global agricultural markets perform over the next two years; that growth, combined with lower net working capital, should generate solid free cash flow that we'll use to reduce net debt over the next two years. That puts us in position to refinance our debt on attractive terms; in summary, our business continues to outperform our peers in a difficult market. The cost initiatives we took earlier this year are now delivering operating leverage, and we're building a pipeline of new products that will drive growth into 2028 and beyond. We have more work to do, and we'll continue to assume the external environment will do us no favors. We'll keep controlling what we can control and executing our plan for growth, efficiency, and greater profitability; with that, operator, you can open the call for questions.

Jeff Bronchick analyst
#5

Good afternoon, gentlemen. Dak, could you go into a little more detail on that $5 million acquisition—in particular, what does it bring us on the product side? You mentioned a revenue figure, so maybe you could give us that revenue number again, together with the profitability attached to it, and walk us through how it fits and why this deal makes sense right now?

Dak Kaye executive
#6

Thank you, Jeff. I appreciate the question, and it's a great one. This is one I'm glad to answer. Product acquisitions have been part of this company's DNA going back a long way. Being able to do these kinds of product acquisitions again matters to us. Compared with what we've done historically, this acquisition was fairly small, but it shows that we're laying the groundwork to get back to where we once were. To be specific: a portfolio of four products, mainly in specialty crops and niche crops, though these carry higher margins and are branded—precisely the sort of thing we succeeded with before, buying branded portfolios from the basic manufacturers and extending the products' life. These registrations sit in the US; they are US registrations. Along with them we picked up certain technical registrations too, which lets us build on these acquisitions beyond the branded products we bought. Mixtures and formulations are possible as well. On value: we paid $5 million upfront, and a $4.5 million payment comes due in another year, so the total value of the acquisition was $9.5 million. We deferred the purchase price, and I'd say it carries a nice, nice net present value on the return of our investment. What this adds to the figure we communicated on this earnings call is $15 million to $20 million, and within that 15% to 20% range sits the contribution we see coming through. That figure also accounts for the distribution agreement we signed with Sipcam Agro at the end of the quarter in the specialty business. I've known Sipcam for many, many years and have done business with them. They have some nice products that are very familiar to us and that we're excited about launching as we speak into the fourth quarter of specialty market. We're really excited about returning to what we were good at as a company—extending the life of these branded products, higher-margin products, and also doing distribution into the specialty business. Thank you, Jeff.

Jeff Bronchick analyst
#7

So these figures are included in what you're expecting for Q4? Are they already landing now, or do they belong to 2027?

Dak Kaye executive
#8

They're landing now. They're landing now — plus the Duro LQ we're bringing out, along with the other new products we've developed organically, the smaller ones. On top of those, the Syngenta portfolio, and the portfolio of four products, just so that's clear, and also Sipcam Agro products entering the specialty market, all of that is folded into the new product figures on the slide for 20 for the fourth quarter of '26.

Jeff Bronchick analyst
#9

No, I understand. It's November 9th, whatever. You're still in the ag business—when you talk about fourth quarter guidance, things like prepays and cash flow, what percentage of your life is already baked for the fourth quarter at this point, versus what's still subject to change?

Dak Kaye executive
#10

I wish I could tell you it was baked. That's not how it works. A lot of work remains in the fourth quarter. We have a refocused and energized commercial organization, starting at the very top—bringing Mike DiPaolo over in the chief commercial officer function earlier this year, giving the reins to all of the markets, and brought in Markelt, who I've worked with before, to run US crop, and then we've also got some additions in the specialty business as well; we've brought in new people, a new energized team with a clear plan to execute for the fourth quarter. I can't say it's all baked in; that's just not how the business runs, how the industry runs. Especially here in the US.

Dak Kaye executive
#11

Thank you, operator. I'd like to wrap up by once more recapping the position we're in today and the direction we're taking. In a very tough market, our business keeps outdoing our competitors. Importantly, the cost actions we implemented earlier this year are now producing operating leverage, and we're assembling a pipeline of new products that will fuel growth into 2028 and beyond. Through distribution agreements and brand acquisitions finished this quarter, we've added several more products to that expanding pipeline. Going forward, we'll keep hunting for opportunities of this kind to further bolster our growth initiatives; there's more work ahead of us, and we'll continue to assume the external environment will do us no favors; we'll keep controlling what we can control and executing our plan for growth, efficiency, and greater profitability. As a reminder, our top near-term priority remains getting our EBITDA margin into double digits as soon as possible. Even with today's challenging environment, we feel good about it. On the top line, we expect to hit an annualized run rate of more than $600 million in sales by the back half of 2028, roughly 20% above our 2025 level. Thank you, everyone, for joining us today. We appreciate your continued support, and we look forward to updating you on our full-year 2026 results when we report our fourth-quarter and full-year results for 2026 in early 2027. Thank you.

Operator operator
#12

Appreciate it — that brings us to the end of today's conference call. You're welcome to disconnect now, and we hope the rest of your day is wonderful. Thanks again for joining us.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete American Vanguard Corporation transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to American Vanguard Corporation earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.